Medical Patent News RSS Feed - Medical Patent News

USPTO grants patent for low-cost dry powder inhaler to Hovione

USPTO grants patent for low-cost dry powder inhaler to Hovione

Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. [More]
U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"). [More]
Actavis gets favorable ruling in patent suit against generic Lialda

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). [More]
Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets. [More]
GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment. [More]
Actavis files ANDA with FDA to market  Colchicine Tablets USP

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. [More]
Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today announced that the United States Patent and Trademark Office has issued five new patents directed to the Subchondroplasty® Procedure, the innovative new joint preservation procedure developed by Zimmer Knee Creations: U.S. Patent No. 8,551,178, U.S. Patent No. 8,574,303, U.S. Patent No. 8,608,802, U.S. Patent No. 8,617,166 and U.S. Patent No. 8,623,089. [More]
New drug patent may help overcome problems associated with MDR-TB

New drug patent may help overcome problems associated with MDR-TB

A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics. [More]
Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery." [More]
NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth. [More]
New patent allows 22 claims surrounding Reverse Medical’s "MVP" technology platform

New patent allows 22 claims surrounding Reverse Medical’s "MVP" technology platform

Reverse Medical Corporation announced today that the United States Patent Office has notified the Company that a new patent has issued entitled "Embolic Implant and Method of Use". [More]

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms. [More]

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). [More]
Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

​A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury. [More]
Impact Sports Technologies receives 18th patent for mobile optical heart rate monitoring technology

Impact Sports Technologies receives 18th patent for mobile optical heart rate monitoring technology

Impact Sports Technologies, Inc., the industry leader in innovative motion resistant strapless heart rate applications, has received its 18th patent, featuring the use of its mobile optical heart rate monitoring technology with a mobile communications device. [More]
Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. [More]
Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. [More]
Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

A Skidmore College alumnus and professor have been awarded U.S. Patent No. 8,598,150 for use of an antioxidant compound that shows promise in the treatment of obesity and related disorders, such as type-2 diabetes. [More]

USPTO rejects NIKKEN's effort to invalidate Imagenetix's patent

Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent. [More]
GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma. [More]